NASD · Healthcare · Health Information Services · Switzerland
SOPHiA Genetics SA is a small cap company (market value between $300 million and $2 billion) in the Health Information Services industry.
Intrinsic value, DCF valuation, financial health and value investing analysis for the SOPHiA Genetics SA stock.
Overvalued: intrinsic value $1.14 per share, market price $7.63, margin of safety -569.2% (as of 2026-10-30).
A 0.9x revenue multiple, discounted for its losses, values the shares at $1.14; the price of $7.63 is 569% above that value.
All 41 Health Information Services stocks
12 more in this industry show a wider margin of safety.
SOPH is overvalued (as of the 2026-10-30 close). A 0.9x revenue multiple, discounted for its losses, values the shares at $1.14; the price of $7.63 is 569% above that value.
$1.14 per share (as of the 2026-10-30 close), against a market price of $7.63. That is a margin of safety of -569.2%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.